CHAPEL HILL, N.C., Sept. 3 /PRNewswire/ -- The Medical Affairs function arguably plays the most critical role in a biopharmaceutical organization, with heavy responsibilities across areas such as clinical development, scientific publications, KOL development, and medical education. These areas must operate effectively for new products to succeed. Appropriate spending across these activities is one of the challenges facing the Medical Affairs function as it attempts to balance its different roles across the organization.
According to recent Best Practices, LLC research, 37 percent of Medical Affairs spending, on average, is allocated for medical/clinical research, with the top quartile of respondents spending more than 60 percent for the clinical function. Meanwhile, medical education takes up 18 percent of allocations, according to the study.
"Medical Affairs Resources, Structures and Trends" highlights trends in budget and staffing for Medical Affairs groups to help leaders in Medical Affairs effectively and efficiently meet the myriad roles of the function. The 45-page report also identifies current organizational approaches for Medical Affairs and current trends and challenge the function is facing.
Twenty-two organizations participated in this study, including: Amgen, AstraZeneca, Bayer Healthcare, BMS, Genentech, J&J Vision Care, Novartis, Novo Nordisk, Schering-Plough, Solvay, Vertex and others.
"Medical Affairs Resources, Structures & Trends" covers key topics such as:
- Organizational Structure
- Reporting Relationship
- Job Level of Group Leader
- Geographic Span
- Budget Allocation by Medical Affairs Function
- Percent of Budget Allocated for Outsourcing
- Recent and Anticipated Changes in Resource Levels
- Impact of Medical Affairs Functions on Company Success